Skip to main content

3 Result(s)

within Michelle Padget Remove this filter

and

  1. Article

    Open Access

    Correction to: Immunotherapy Utilizing the Combination of Natural Killer– and Antibody Dependent Cellular Cytotoxicity (ADCC)–Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition

    Following publication of the original article [1], an error was noted in the GAPDH in the western blot depicted in Figure 4b.

    Kathleen E. Fenerty, Michelle Padget… in Journal for ImmunoTherapy of Cancer (2019)

    Download PDF (428 KB) View Article

  2. Article

    Open Access

    Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

    Poly (ADP-ribose) polymerase inhibitors (PARPi) prevent single-stranded DNA repair. Olaparib is a PARPi approved for the treatment of BRCA mutant ovarian and breast carcinoma. Emerging clinical data suggest a ...

    Kathleen E. Fenerty, Michelle Padget… in Journal for ImmunoTherapy of Cancer (2018)

    Download PDF (3240 KB) View Article

  3. Article

    Open Access

    Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies

    Natural killer (NK) cells recognize and lyse target tumor cells in an MHC-unrestricted fashion and complement antigen- and MHC-restricted killing by T-lymphocytes. NK cells and T-lymphocytes mediate early kill...

    Jay Friedman, Megan Morisada, Lillian Sun… in Journal for ImmunoTherapy of Cancer (2018)

    Download PDF (2031 KB) View Article